Literature DB >> 20663862

Overexpression of CD133 promotes drug resistance in C6 glioma cells.

James M Angelastro1, Michael W Lamé.   

Abstract

Glioblastoma multiforme is an extremely aggressive and clinically unresponsive form of cancer. Transformed neoplastic neural stem cells, resistant to chemotherapy and radiation therapy, are thought to be responsible for the initial tumor formation and the recurrence of disease following surgical resection. These stem cells express multidrug resistance markers along with CD133. We show that ectopic overexpression of CD133 in rat C6 glioma cells leads to significant reluctance to undergo apoptosis from camptothecin and doxorubicin. Although p53 was upregulated in CD133-overexpressing glioma cells treated with DNA-damaging agents, apoptosis seems to be p53 independent. At least one ABC transporter, rat P-glycoprotein/ABCB1, was upregulated by 62% in CD133(+) cells with a corresponding increase in activity. Thus, the combination of higher P-glycoprotein mRNA transcription and elevated transporter activity seems to contribute to the protection from cytotoxic reagents. In conclusion, previous investigators have reported that resilient cancer stem cells coexpress CD133 and ABC transporters with increased reluctance toward apoptosis. Our data suggest that CD133 may contribute to the observed resistance to apoptosis of CD133(+) cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663862      PMCID: PMC2923683          DOI: 10.1158/1541-7786.MCR-09-0383

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  58 in total

Review 1.  Neural stem cells and the origin of gliomas.

Authors:  Nader Sanai; Arturo Alvarez-Buylla; Mitchel S Berger
Journal:  N Engl J Med       Date:  2005-08-25       Impact factor: 91.245

Review 2.  Brain tumour stem cells.

Authors:  Angelo L Vescovi; Rossella Galli; Brent A Reynolds
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

3.  AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family?

Authors:  D Corbeil; K Röper; A Weigmann; W B Huttner
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

4.  The plasma membrane polarity of human biliary epithelial cells: in situ immunohistochemical analysis and functional implications.

Authors:  J Y Scoazec; A F Bringuier; J F Medina; E Martínez-Ansó; D Veissiere; G Feldmann; C Housset
Journal:  J Hepatol       Date:  1997-03       Impact factor: 25.083

5.  Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5.

Authors:  J M Angelastro; P D Canoll; J Kuo; M Weicker; A Costa; J N Bruce; L A Greene
Journal:  Oncogene       Date:  2006-02-09       Impact factor: 9.867

Review 6.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 7.  AC133/CD133/Prominin-1.

Authors:  Sergey V Shmelkov; Ryan St Clair; David Lyden; Shahin Rafii
Journal:  Int J Biochem Cell Biol       Date:  2005-04       Impact factor: 5.085

8.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

9.  p53 is cleaved by caspases generating fragments localizing to mitochondria.

Authors:  Berna S Sayan; A Emre Sayan; Richard A Knight; Gerry Melino; Gerald M Cohen
Journal:  J Biol Chem       Date:  2006-03-10       Impact factor: 5.157

10.  Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas.

Authors:  Heike Immervoll; Dag Hoem; Per Øystein Sakariassen; Ole Johnny Steffensen; Anders Molven
Journal:  BMC Cancer       Date:  2008-02-08       Impact factor: 4.430

View more
  31 in total

Review 1.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

2.  A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs.

Authors:  Jingping Xie; Chunxia Wang; John Virostko; H Charles Manning; Wellington Pham; Joshua Bauer; John C Gore
Journal:  Chembiochem       Date:  2013-07-24       Impact factor: 3.164

Review 3.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

4.  Chemoresistance to 5-FU inhibited by 635 nm LED irradiation in CD133+ KB cell line.

Authors:  Donghwi Kim; Mineon Park; Hyunwoong Jang; Hoon Hyun; Wonbong Lim
Journal:  Lasers Med Sci       Date:  2017-09-27       Impact factor: 3.161

Review 5.  CD133 as a regulator of cancer metastasis through the cancer stem cells.

Authors:  Geou-Yarh Liou
Journal:  Int J Biochem Cell Biol       Date:  2018-11-03       Impact factor: 5.085

6.  CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.

Authors:  G Xi; E Hayes; R Lewis; S Ichi; B Mania-Farnell; K Shim; T Takao; E Allender; C S Mayanil; T Tomita
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

7.  Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells.

Authors:  Shuzheng Song; Guoqing Pei; Yaqiong Du; Jugang Wu; Xiaochun Ni; Shoulian Wang; Bojian Jiang; Meng Luo; Jiwei Yu
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

Review 8.  Cancer stem cell marker glycosylation: Nature, function and significance.

Authors:  Brody W Mallard; Joe Tiralongo
Journal:  Glycoconj J       Date:  2017-06-17       Impact factor: 2.916

9.  Effect of CD133 overexpression on the epithelial-to-mesenchymal transition in oral cancer cell lines.

Authors:  YeonHee Moon; Donghwi Kim; HongMoon Sohn; Wonbong Lim
Journal:  Clin Exp Metastasis       Date:  2016-05-02       Impact factor: 5.150

10.  Targeted delivery of vitamin D3-loaded nanoparticles to C6 glioma cell line increased resistance to doxorubicin, epirubicin, and docetaxel in vitro.

Authors:  Nargess Maleklou; Abdolamir Allameh; Bahram Kazemi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-08-08       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.